Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.055 USD | +6.40% | -28.57% | -12.71% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.71% | 244M | |
+13.27% | 227B | |
+13.98% | 192B | |
+17.71% | 136B | |
+28.56% | 108B | |
+1.67% | 64.07B | |
+17.63% | 52.1B | |
+7.04% | 51.87B | |
+10.86% | 44.33B | |
+5.32% | 36.75B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Adjusts Price Target on NeuroPace to $2.50 From $3.50, Maintains Underweight Rating